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1. Introduction 
Factor X is a plasma glycoprotein that is involved 
in both the intrinsic and extrinsic pathway of blood 
coagulation. During the coagulation process, factor X 
is converted to factor Xa (EC 3.4.21.6), a serine pro- 
tease catalysing the activation of prothrombin and 
the enzymatic onversion of several other coagulation 
factors [ 1,2]. One of the substrates of factor Xa is its 
zymogen, factor X. In the bovine system, the cleavage 
of factor X by factor Xa can result in the activation 
of factor X [3-51. In the human system however, 
factor Xa cleaves a peptide from factor X that con- 
tains the active-site serine residue [6]. Thus, the bovine 
and human system differ with respect o the effect of 
factor Xa on factor X (activation vs inactivation). 
Here, the proteolysis of factor X by factor Xa in 
various combinations of human and bovine proteins 
is described. We conclude that the enzymes of both 
species have similar substrate specificities and that 
structural differences between the human and bovine 
zymogen account for the different autocatalytic path- 
ways. 
2. Materials and methods 
Bovine factor X and factor Xa were prepared as in 
[78]. Human factor X was purified as in [6]. Human 
factor Xa was prepared by the complete activation of 
purified factor X using the purified factor X-activator 
from Russell’s viper venom [9], as detailed elsewhere 
(K. M., R. M. B., submitted). Phospholipid vesicles 
were prepared by dispersing a phospholipid extract 
from human brain [6] in 100 mM NaCI, 50 mM Tris- 
HCl (pH 7.5) using a Branson (model B12) sonifier. 
Lipid phosphorus was quantitated after HC104 
combustion according to [lo]. SDS-Polyacrylamide 
gel electrophoresis was performed as in [6]. Factor 
Xa activity was measured spectrophotometrically by 
adding samples to cuvettes containing 5mM EDTA, 
100 pg/ml ovalbumin and 0.22 mM of the substrate 
Benzoyl-Be-Glu(piperidyl)-Glu-Arg-p-nitroanilide 
(S 2337, Kabi Diagnostica, Sweden) in 200 mM NaCl, 
50 mM Tris-HCl, pH 8.0 (final vol. 1 ml), and by 
recording AN5 at 37°C. The factor Xa activity in the 
samples was expressed in r&at/ml. Factor X concen- 
trations were derived from the factor Xa activities 
measured after the complete conversion of the factor 
X in the samples to factor Xa using Russell’s viper 
venom; under the assay conditions the factor X con- 
centration in normal human plasma is equivalent to a 
factor Xa activity of 6.8 nkat/mI. 
3. Results and discussion 
Fig.la shows the development of factor Xa activity 
during the incubation of bovine factor Xa with bovine 
and human factor X in the presence of Ca*+ and phos- 
pholipid. When bovine factor X is the substrate, the 
factor Xa activity increases after an initial lag period; 
this confirms the activation of bovine factor X by 
bovine factor Xa [3-51. However,when human factor 
X is the substrate, the factor Xa activity remains con- 
stant,indicating that bovine factor Xa does not activate 
human factor X. Similar results are obtained when 
human factor Xa is used in stead of bovine factor Xa 
(tiglb). 
Fig.2 shows the SDS-polyacrylamide gels of 
samples taken after different incubation times from 
the reaction mixtures described in fig.1. Bovine and 
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Activation of factor X by factor Xa. Bovine (0) and 
human (0) factor X (equivalent o 34 nkat/ml factor Xa after 
complete activation by Russell’s viper venom) were incubated 
with bovine (a) and human (b) factor Xa (1.1 nkat/ml) in the 
presence of phospholipid (100 MM) and CaCl, (10 mM) in 
100 mM NaCl, 50 mM Tris-HCl (pH 7.5) at 37°C. At the 
times indicated, samples from the incubation mixtures were 
assayed for factor Xa activity. 
human factor Xa catalyse ssentially the same conver- 
sions when i cubated with either bovine or human 
factor X. 
Bovine factor X (M, 63 000) is converted to a prod- 
uct with M, 49 000 via an intermediate (M, 58 000). 
In the same incubation mixture, factor Xa activity 
develops after an initial lag period, suggesting that 
only the final (M, 49 000) product has factor Xa 
activity. Interpretation of these observations based on 
the data in [3,4,8 ,l 1 ,121 indicates that the Mr 
58 000 component is formed by the cleavage of a 
small peptide from the C-terminal portion of the 
heavy chain, whereas the ikfr 49 000 component is 
formed by the subsequent removal of a glycopeptide 
(the activation peptide) from the N-terminal portion 
of the heavy chain. The latter cleavage isaccompanied 
by the appearance of factor Xa activity (see fig.1). It 
should be noted that the proteolysis of bovine factor 
X in the presence of human factor Xa (see fig2b) 
may result from the action of both the human factor 
Xa added and of the bovine factor Xa formed. How- 
ever, since no significant amounts of factor Xa 
(<l nkat/ml) are formed in the absence of added fac- 
tor Xa (data not shown), the conversions observed in 
fig2b are at least initiated by human factor Xa. 
Human factor X (M, 68 000) has a molecular mass 
slightly higher than that of bovine factor X (M, 
63 000). It is converted to products with M, 55 000, 
34 000,2 1000 and 13 000 (see fig.2). These products 
Fig.2. Proteolysis of factor X by factor Xa. The incubation 
mixtures were those in tig.1, containing bovine factor X and 
bovine factor Xa (a), bovine factor X and human factor Xa 
(b), human factor X and bovine factor Xa (c), and human 
factor X and human factor Xa (d). Each panel shows 10% 
SDS-polyacrylamide gels of samples withdrawn after (from 
left to right) 0, 1,2.5,4 and 11 h incubation. 
correspond with factor TX, factor arX, fragment* 
and fragment? [6]. The first product, factor yX (M, 
55 000), is formed by the cleavage of fragment? (M, 
13 000) from the C-terminal region f the heavy chain. 
Since fragment? contains the active-site serine residue 
[6], the subsequent conversion of factor 7X to factor 
&TX (M, 34 000) by the removal of fragment* (the 
activation peptide, M, 21 000) from the N-terminal 
region of the heavy chain cannot result in the appear- 
ance of factor Xa activity (cf. fig.1). 
In conclusion, both bovine and human factor X 
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are cleaved by factor Xa in two subsequent s eps: in 
each case the cleavage of a C-terminal peptide from 
the heavy chain (step 1) is followed by the removal 
of the activation peptide from the N-terminal portion 
of the heavy chain (step 2). In the bovine system, the 
C-terminal peptide (M, 5000) is not essential for fac- 
tor Xa activity, whereas in the human system this 
fragment (M, 13 000) contains the active-site serine 
residue. Since the substrate specificity of bovine fac- 
tor Xa is similar to that of the human enzyme (cf. 
fig.l,2), this discrepancy must originate from struc- 
tural differences between the C-terminal regions of 
the heavy chain of bovine and human factor X. 
Human and bovine factor X also differ with respect 
to the N-terminal region of the heavy chain [ 131: the 
human activation peptide has a higher carbohydrate 
content and contains 20-30 amino acids more than 
its bovine counterpart. This explains the difference in 
Afr value between human (68 000) and bovine (63 000) 
factor X. 
At present it is not clear whether these structural 
differences contribute to differences in the mechanism 
of factor X-activation in the bovine and human species. 
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